Navigation Links
Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Date:3/25/2009

SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has reached its enrollment target of 400 patients in the SPEAR (Study of Picoplatin Efficacy After Relapse) trial. This global, pivotal Phase 3 trial is evaluating the efficacy and safety of picoplatin in patients with recurrent small cell lung cancer (SCLC) who have failed prior platinum-containing first-line chemotherapy or who have progressed within six months of first-line therapy. Patients have been enrolled at more than 100 clinical trial sites in 16 countries in Europe, South America and Asia.

"Completion of patient enrollment in our pivotal Phase 3 SPEAR trial represents an important milestone for Poniard. We accomplished this ahead of internal projections, which allows us to keep on schedule to complete the clinical data analysis and initiate the filing of a rolling New Drug Application with the U.S. Food and Drug Administration for picoplatin in SCLC this year," said Jerry McMahon, Ph.D., chairman and chief executive officer of Poniard. "We believe that picoplatin will provide a survival benefit for SCLC patients who have failed platinum-based therapy consistent with survival data we have previously generated in two independent Phase 2 trials. We also expect the data will show that picoplatin overcomes resistance in patients treated with current platinum-based chemotherapies. This would be a new use for a platinum chemotherapy agent. We are also continuing to analyze additional clinical data from our picoplatin Phase 2 trials in first-line treatment for metastatic colorectal and prostate cancers and will report on them later this year."

"We are pleased to have completed trial enrollment ahead of schedule," said Robert De Jager, M.D.
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... YORK , August 3, 2015 ... published by Persistence Market Research "Global Market Study ... to Witness Highest Growth by 2022", the ... US$15 Bn by the end of 2015 and is ... from 2015 to 2022, to account for US$23.7 ...
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 ... development agreements between biotech companies, military surgical ... solutions & therapies with regards to severe ... positive clinical enhancements for regenerative medicine and ... recent developments, partnerships and advancements in focus ...
(Date:8/3/2015)... , Aug. 3, 2015 VWR (NASDAQ: ... services and solutions, announces the redesign of its global website, ... When visiting the new site, guests will enjoy ... colors and vivid images.  Each country site now includes: ... to Z product menu; and , the ability to ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6VWR's New Website Redesign Provides Improved Functionality for Customers 2
... 5, 2012  Quest Diagnostics Incorporated (NYSE: DGX ), ... announced that it will report fourth quarter and full year ... January 24, 2012 before the market opens. It will hold its ... a.m. Eastern Time on that day. The public ...
...  DURECT Corporation (Nasdaq: DRRX ) announced today ... study for POSIDUR® known as BESST (Bupivacaine Effectiveness and ... relief depot that utilizes DURECT,s patented SABER™ technology to ... three days of pain relief after surgery.  BESST was ...
Cached Medicine Technology:Quest Diagnostics to Release Fourth Quarter and Full Year 2011 Financial Results 2DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial) 2DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial) 3DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial) 4DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial) 5
(Date:8/3/2015)... ... August 03, 2015 , ... ... development of it’s new program “Designing Secure Healthcare Systems” This three-day, highly ... technology leaders from healthcare organizations with access to the tactics, techniques and practices ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive ... occurs naturally in the body and helps absorb and breakdown fat cells. Previously, plastic ... These are invasive procedures and very expensive for most people. Now with Kybella, there ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from ... Cells Found to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses ... the report, the new study showed that harvesting stem cell-rich bone marrow from the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Illinois Health & ... July 31. , The acquisition includes all of IBAM NA’s cyclotron sites and ... have both, a robust regionally located business, as well as a large manufacturing hub ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... firm, announced today that Joe Williams has joined its growing California employee benefits ... HUB's differentiated service model to his clients. Mr. Williams will be joining the ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... DENVER, June 24 The National Sports Center for the Disabled and American ... Classic from Friday, July 17th to Sunday, July 19th at the Winter Park ... with a wide variety of well-marked trails for all levels of riders and ... , World Class Mountain Biking! , ...
... researchers say , , WEDNESDAY, June 24 (HealthDay ... well in an early clinical trial against breast, ovarian ... to developing these malignancies. , Women who carry BRCA1 ... and ovarian cancer, and among men these mutations are ...
... 24 Validation and Compliance Institute (VCI), which provides ... industries, will offer a series of Dietary Supplement Good ... division of NSF International. , , ... GMP regulations for dietary supplements, which the US Food ...
... 24 Speaker Nancy Pelosi held a brief a press availability ... , Jim Douglas of Vermont , and Chris Gregoire ... to discuss health care reform. Below are their remarks: ... indeed to welcome three very distinguished governors to The Speaker,s Office - ...
... , ROCHESTER, Minn., June 24 The Mayo Clinic ... collaborative symposium on innovations in health care experience and ... open to the public. It will feature nationally recognized ... in health care delivery models, including Web-based tools. The ...
... biomarkers in patients with only mild memory problems , ... disease can be detected in the cerebrospinal fluid in ... study suggests. , University of Gothenburg researchers analyzed cerebrospinal ... typical pattern of biomarkers known as the "CSF AD ...
Cached Medicine News:Health News:18th Annual Fat Tire Classic Benefiting the National Sports Center for the Disabled & the American Red Cross Mile High July 17th - 19th, 2009 2Health News:New Cancer Drug Fights Tumors in Those With BRCA Mutations 2Health News:New Cancer Drug Fights Tumors in Those With BRCA Mutations 3Health News:Validation & Compliance Institute, LLC, to Provide Dietary Supplement GMP Training for NSF International 2Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 2Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 3Health News:Pelosi, Governors' Remarks Before Meeting on Health Care 4Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 2Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 3Health News:Clues to Alzheimer's Spotted Earlier in Disease 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: